Copertina

Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kazuki Takada, Shinkichi Takamori, Mototsugu Shimokawa, David J. Pinato, Alessio Cortellini
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	International Journal of Cancer
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Impact of Anti‐Inflammatory Drug Therapy on the Efficacy of First‐Line Atezolizumab Treatment in Patients With Advanced Non‐Small Cell Lung Cancer: An Integrated Analysis of Five Randomized Controlled Trials
di: Kazuki Takada, et al.
Pubblicazione: (2026)

Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non‐small cell lung cancer
di: Shinkichi Takamori, et al.
Pubblicazione: (2025)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
di: Tadashi Nishimura, et al.
Pubblicazione: (2024)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
di: Han Li, et al.
Pubblicazione: (2024)

Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
di: Ayako Morita, et al.
Pubblicazione: (2024)

Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
di: Saira Afzal, et al.
Pubblicazione: (2024)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
di: Gen Lin, et al.
Pubblicazione: (2024)

The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors
di: I. M. Horstman, et al.
Pubblicazione: (2024)

Magnetic resonance imaging features of hypophysitis in patients with cancer treated with immune checkpoint inhibitors
di: Anna Angelousi, et al.
Pubblicazione: (2025)

Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade
di: Kyu‐Young Oh, et al.
Pubblicazione: (2024)

Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
di: Chuang Yang, et al.
Pubblicazione: (2024)

Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150
di: Yue Zhou, et al.
Pubblicazione: (2024)

KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers
di: Yuedian Ye, et al.
Pubblicazione: (2025)

The effect of common medications on the efficacy of immune checkpoint inhibitors
di: Daria Brinzevich, et al.
Pubblicazione: (2025)

Microsurgical regenerative approach to intrabony defects
di: Pierpaolo Cortellini, et al.
Pubblicazione: (2026)

Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment
di: Jiayi Wu, et al.
Pubblicazione: (2024)

Effective and safe use of immune checkpoint inhibitors for non‐small cell lung cancer in people living with HIV
di: Rebekka Mispelbaum, et al.
Pubblicazione: (2025)

Large‐vessel vasculitis induced by pegfilgrastim and immune checkpoint inhibitor in a patient with small‐cell lung cancer
di: Keisuke Shiraha, et al.
Pubblicazione: (2024)

Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
di: Jie Zhao, et al.
Pubblicazione: (2024)

The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB−IV non‐small cell lung cancer
di: Lina Yi, et al.
Pubblicazione: (2024)

Non-prescription proton-pump inhibitors for self-treating frequent heartburn: the role of the Canadian pharmacist
di: David ARMSTRONG
Pubblicazione: (2016)

Correction to “The effect of common medications on the efficacy of immune checkpoint inhibitors”
Pubblicazione: (2026)

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
di: Xiu Chen, et al.
Pubblicazione: (2024)

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?
di: Rocco Simone Flammia, et al.
Pubblicazione: (2026)

Revisiting the impact of common medications on immune checkpoint inhibitor efficacy
di: Parham Habibzadeh, et al.
Pubblicazione: (2026)

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
di: Damien Sanogo, et al.
Pubblicazione: (2025)

Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
di: Takanori Ito, et al.
Pubblicazione: (2024)

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer
di: Zhuo Cheng, et al.
Pubblicazione: (2024)

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
di: Georges Gebrael, et al.
Pubblicazione: (2024)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
di: Yuki Haruta, et al.
Pubblicazione: (2024)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
di: Yuan Meng, et al.
Pubblicazione: (2024)

Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps
di: Duo Chen, et al.
Pubblicazione: (2024)

Incidence and risk factors of immune‐related adverse events induced by immune checkpoint inhibitors among older adults with non‐small cell lung cancer
di: Yiran Rong, et al.
Pubblicazione: (2024)

Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade
di: Lucy S. Wang, et al.
Pubblicazione: (2024)

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma
di: Matheus Henrique Dias, et al.
Pubblicazione: (2025)

The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
di: Phuong, Linh Nguyen, et al.
Pubblicazione: (2025)

Stevens‐Johnson syndrome and toxic epidermal necrolysis‐like eruptions in patients treated with immune checkpoint inhibitors: a systematic review
di: Christeebella O. Akpala, et al.
Pubblicazione: (2024)

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan
di: Masako Shomura, et al.
Pubblicazione: (2024)

Delayed onset eruptive keratoacanthomas following immune checkpoint inhibitor therapy
di: Megan M. Tran, et al.
Pubblicazione: (2024)

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy
di: Jie Bian, et al.
Pubblicazione: (2024)